Clearside Biomedical announced that additional data from PEACHTREE, the company’s pivotal Phase 3 trial of XIPERE in patients with uveitic macular edema, were presented at the American Academy of Ophthalmology 2018 Annual Meeting by Rahul N. Khurana, MD, Vitreoretinal Surgeon at Northern California Retina Vitreous Associates, Clinical Associate Professor in Ophthalmology at UCSF Medical Center, and a Principal Investigator for PEACHTREE. At the meeting, Dr. Khurana shared XIPERE’s efficacy data in resolving uveitic inflammation for the first time at a scientific congress. Dr. Khurana also presented new analyses of resolution of clinically significant vitreous haze, as well as the mean change from baseline in best corrected visual acuity in patients with uveitis in each anatomical location, providing further support for the clinical profile of XIPERE in the potential treatment of uveitic macular edema.In the PEACHTREE trial, at week 24, 40.9% of patients with baseline scores of 2+ vitreous haze, based on the Standardization of Uveitis Nomenclature scale, experienced resolution in the XIPERE arm, compared to 0% of patients in the control arm who underwent a sham procedure. Additionally, in the XIPERE arm, 68% of patients with any baseline level of vitreous haze, 72% of patients with anterior chamber cell inflammation and 74% of patients with anterior chamber flare had their inflammation resolve, compared to 23%, 17% and 20%, respectively, of patients in the control arm. Resolution was defined as achieving a score of zero on the applicable SUN scale, implying no measureable inflammation was present.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.